Endo Pharmaceuticals' CEO David Holveck, a Johnson & Johnson alum, is modeling his company after the Big Pharma. Gabelli & Co analyst Kevin Kedra notes that Lidoderm ...
Kedra estimates Lidoderm will account for 47% of 2010 sales, or $787 million of $1.7 billion in revenue. Lidoderm is a patch containing the painkiller lidocaine.
